You are here

New NIST Protein Could Spur Biopharmaceutical Innovation

Antibody adds to toolkits of biologics manufacturers, regulators

The National Institute of Standards and Technology (NIST) has issued one of the world’s most intricate measurement standards: an exhaustively analyzed antibody protein that the biopharmaceutical industry will use to help ensure the quality of treatments across a widening range of health conditions, including cancers, autoimmune disorders, and infectious diseases.

The standard is an antibody protein—consisting of more than 20,000 atoms—analyzed so thoroughly that the material can be used by organizations around the globe to verify and improve their analytical methods for quality control.

Donated by MedImmune, the global biologics research and development arm of AstraZeneca, and then characterized by NIST and collaborators, the new reference material (RM)—NIST RM 8671—is a monoclonal antibody (mAb). This class of therapeutic compounds is produced in the lab by living cells, usually from mouse or hamster cell lines. Uniform in composition and structure, mAbs account for five of the 10 top-selling drugs and more than $75 billion in annual sales worldwide. According to one estimate, about 300 mAb-based therapeutics are being evaluated for safety and effectiveness in clinical trials.

Antibodies work by binding to and inactivating proteins involved in disease pathways; mAbs also can act like guided missiles that precisely deliver therapeutic payloads of chemicals or radiation.

Chosen for development in consultation with industry, NIST RM 8671 is an important addition to the toolkits of biological drug manufacturers and their suppliers and regulators. It serves as a representative molecule that can be used to determine that methods for assessing product quality are working properly and to evaluate new methods or technologies.

It also provides an industry very mindful of intellectual property concerns with a standard benchmark for everyone, from aspiring startup to multinational firm to regulator.

As such, “it can serve as a common benchmark for future innovation,” explained NIST research chemist John Schiel, who led an international effort that explored and demonstrated uses of the reference mAb. “The material has many anticipated applications—in establishing industry-recognized best practices, for example—and we are hoping that there will be many future uses that we can’t predict from the current state of practice in biopharmaceutical research and production.”

Industry experts have indicated that a universally available “public” mAb, characterized and distributed by NIST, will allow better assessment of existing analytical methods and potentially faster adoption of new technologies.

In fact, the utility of the reference material already has been demonstrated by more than 100 collaborators from companies, regulatory agencies, and universities around the world. As documented in a three-volume book set published by the American Chemical Society (ACS), the partners engaged in a “crowdsourcing” exercise. Research teams used current and emerging analytical methods to, in effect, take measure of the mAb from many different vantage points before NIST formally released it as a standard.

“NISTmAb will act as a shared catalyst for developing, troubleshooting, adapting, and bridging analytical technologies,” explained Oleg Borisov, Director of Analytical Development at Novavax. “The book from ACS demonstrates this. It presents extensive information and data on a single monoclonal antibody, and describes the methodologies that enabled this state-of-the-art characterization. The result is a comprehensive characterization dossier that should serve as a valuable reference to researchers.”

Schiel, Borisov, and Darryl Davis, Associate Director of Biologics Research at Janssen R&D, are editors of the set, State-of-the-Art and Emerging Technologies for Therapeutic Monoclonal Antibody Characterization.

Each vial of NIST RM 8671 will contain 800 mcL of the NISTmAb at a concentration of 10 mg/mL. The standard comes with the results of NIST measurements that provide a thorough profile of the standard protein, Schiel said, providing details on size, concentration, composition, structure, purity, stability, and other attributes.

Kurt Brorson, a research biologist in the Office of Biotechnology Products at the FDA, said the new standard can be used as a “universal system suitability test” for many of the assays and test methods used to assure the quality of mAbs. “The biotech industry can more efficiently cross-validate (measurement) methods at different sites or more efficiently develop platform analytics for related molecules,” he explained.

“The NISTmAb should help in answering a simple, yet critical, question that can consume a disproportionate amount of time when deviations arise with testing; is it the sample or the method that is varying?” said Michael Tarlov, Chief of NIST’s Biomolecular Measurement Division and leader of the NIST-wide Biomanufacturing Program.

During the NISTmAb’s meticulously recorded audition, NIST and its collaborators developed data comparable to that found in a biologics license application submitted to the FDA when a company seeks approval for a new mAb-based therapeutic. These data are available online, along with results of analyses done with still-experimental tools, providing a historical record of NIST RM 8671 that will be updated as more analyses are done and as questions arise and spawn new studies.

Source: NIST; July 28, 2016.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs